Methamphetamine rapidly decreases mouse vesicular dopamine uptake: Role of hyperthermia and dopamine D2 receptors

European Journal of Pharmacology

Volumn 472, Issue 3, 2003, Pages 165-171

  Ugarte, Yvette V ^a   Rau, Kristi S ^a   Riddle, Evan L ^a   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

(Mouse); Dopamine; Methamphetamine; VMAT 2

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CARRIER PROTEIN; DIHYDROTETRABENAZINE; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; METHAMPHETAMINE; METHYLPHENIDATE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG EFFECT; DRUG MECHANISM; HYPERTHERMIA; IMMUNOREACTIVITY; MALE; MONOAMINE RELEASE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RAT; SPECIES COMPARISON;

EID: 0142059611     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01911-3     Document Type: Article

References (27)

1. Battaglia G., Yeh S.Y., DeSouza E.B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29:1988;269-274.
2. Brown J.M., Hanson G.R., Fleckenstein A.E. Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem. 74:2000;2221-2223.
3. Brown J.M., Hanson G.R., Fleckenstein A.E. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors. J. Pharmacol. Exp. Ther. 298:2001;1150-1153.
4. Brown J.M., Riddle E.L., Sandoval V., Weston R.K., Hanson J.E., Crosby M.J., Ugarte Y.U., Gibb J.W., Hanson G.R., Fleckenstein A.E. A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J. Pharmacol. Exp. Ther. 302:2002;497-501.
5. Chapin D.S., Lookingland K.E., Moore K.E. Effects of LC mobile phase composition on retention times for biogenic amines, and their precursors and metabolites. Curr. Sep. 7:1986;68-70.
6. Fleckenstein A.E., Gibb J.W., Hanson G.R. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 406:2000;1-13.
7. Fuller R.W. Neurochemical effects of serotonin neurotoxins: an introduction. Ann. N.Y. Acad. Sci. 305:1978;178-181.
8. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., Caron M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19:1999;2424-2431.
9. Gibb J.W., Kogan F.J. Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn-Schmiedeberg's Arch. Pharmacol. 310:1979;185-187.
10. Graham D.G., Tiffany S.M., Bell W.R. Jr., Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14:1978;644-653.
11. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64:1995;919-924.
12. Hogan K.A., Staal R.G., Sonsalla P.K. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J. Neurochem. 74:2000;2217-2220.
13. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurements with the Folin-phenol reagent. J. Biol. Chem. 193:1951;265-275.
14. Marek G.J., Vosmer G., Seiden L.S. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res. 513:1990;274-279.
15. Miller K.W., Sanders-Bush E., Dingell J.V. p-Chloroamphetamine-species differences in the rate of disappearance and the lowering of cerebral serotonin. Biochem. Pharmacol. 20:1971;500-503.
16. Nath A., Anderson C., Jones M., Maragos W., Booze R., Mactutus C., Bell J., Hauser K.F., Mattson M. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J. Psychopharmacol. 14:2000;222-227.
17. Przedborski S., Jackson-Lewis V., Naini A.B., Jackowec M., Petzinger G., Miller R., Akram M. The parkinsonian toxin 1-methly-4-phenly-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76:2001;1264-1274.
18. Ricaurte G.A., McCann U.D. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann. N.Y. Acad. Sci. 648:1992;371-382.
19. Riddle E.L., Topham M.K., Haycock J.W., Hanson G.R., Fleckenstein A.E. Differential trafficking of the vesicular monoamine transporter-2 caused by methamphetamine and cocaine. Eur. J. Pharmacol. 449:2002;71-74.
20. Sandoval V., Hanson G.R., Fleckenstein A.E. Methylphenidate rapidly redistributes vesicular monoamine transporter-2: role of dopamine receptors. J. Neurosci. 22(19):2002;8705-8710.
21. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J. Pharmacol. Exp. Ther. 304:2003;1181-1187.
22. Schmidt C.J., Gibb J.W. Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid. Eur. J. Pharmacol. 109:1985;73-80.
23. Seiden L.S., Commins D.L., Vosmer G., Axt K., Marek G. Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections. Ann. N.Y. Acad. Sci. 537:1988;161-172.
24. Steranka L.R., Sanders-Bush E. Species differences in the rate of disappearance of fenfluramine and its effects on brain serotonin neurons. Biochem. Pharmacol. 28:1979;3101-3107.
25. Stone D.M., Hanson G.R., Gibb J.W. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology. 26(11):1987;1657-1661.
26. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15:1995;4102-4108.
27. Wagner G.C., Lucot J.B., Schuster C.R., Seiden L.S. alpha-Methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res. 270:1983;285-288.